ພະຈິກ 2021: ການທົດລອງທາງຄລີນິກຄັ້ງທຳອິດຂອງການປິ່ນປົວດ້ວຍເຊນຕ້ານເຊື້ອຈຸລິນຊີ ໄບເມີຣິກ ໂຕຮັບ T (CAR-T) ລຸ້ນຕໍ່ໄປຂອງເກົາຫຼີໃຕ້, ເຊິ່ງຖືກອອກແບບເພື່ອຫຼີກລ່ຽງສັນຍານຈຸດກວດພູມຄຸ້ມກັນ, ໄດ້ດຳເນີນໄປເມື່ອບໍ່ດົນມານີ້.
ສະຖາບັນວິທະຍາສາດ ແລະເທັກໂນໂລຍີຂັ້ນສູງຂອງເກົາຫຼີໃຕ້ (KAIST) ໄດ້ປະກາດໃນວັນພຸດວານນີ້ວ່າ ການທົດລອງທາງຄລີນິກໄລຍະ 1b ຂອງການປິ່ນປົວໂຣກຜີວໜັງ CAR-T ກໍາລັງດຳເນີນຢູ່ສູນການແພດ Samsung ໃນກຸງໂຊລ. ການທົດລອງແມ່ນໄດ້ຮັບການດໍາເນີນການກັບຄົນເຈັບເກົາຫຼີ 10 ຄົນທີ່ໄດ້ relapsed ແລະ refractory diffuse lymphoma ຂະຫນາດໃຫຍ່ B cell. ສິດທິດ້ານການຕະຫຼາດສໍາລັບທໍ່ນັ້ນໄດ້ຖືກໂອນຈາກມະຫາວິທະຍາໄລໄປໃຫ້ບໍລິສັດ Curocell, ເຊິ່ງຮ່ວມກໍ່ຕັ້ງໂດຍອາຈານ Kim Chan-hyuk. Curocell ຮັບຜິດຊອບໂຄງການພັດທະນາທາງດ້ານຄລີນິກຂອງຜູ້ປະຕິວັດ immunotherapy.
In addition, a Phase 2 ການທົດລອງທາງດ້ານການຊ່ວຍ involving seventy participants is going to take place the following year to assess how safe and effective the investigational medication is.
The acronym CAR T, which stands for ຕົວຮັບ antigen chimeric T, is frequently referred to as a miracle cure. This is due to the fact that studies conducted in other countries on terminal blood cancer patients demonstrated that the therapy had a therapeutic effect of more than 80 percent. T cells from a patient are taken from the patient’s blood, genetically enhanced to make them more effective, and then reintroduced to the patient so that they can continue to fight and destroy cancer cells inside the patient’s body.
The research team that was led by Professor Kim of the Department of Biomedical Engineering at the KAIST confirmed an improved anticancer efficacy of CAR-T cells in mice with leukaemia and lymphoma. This was achieved by simultaneously inhibiting programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and ITIM domain (TIGIT), both of which are known to disturb the function of T cells. According to Professor Lee Young-ho, a post-doctoral researcher at KAIST and the first author of the animal model study, this dual blockade of PD-1 and TIGIT is a novel strategy to overcome the immunosuppression of existing CAR-T cells. This strategy was discovered by Prof. Lee Young-ho.
ທ່ານອາດຈະຢາກອ່ານ: ການປິ່ນປົວ CAR T-Cell ໃນເກົາຫລີ
ການຄົ້ນພົບຂອງການສຶກສາໄດ້ຖືກນໍາສະເຫນີໃນບົດຄວາມທີ່ຈັດພີມມາອອນໄລນ໌ໃນເດືອນຕຸລາຂອງການປິ່ນປົວດ້ວຍໂມເລກຸນ.
